Novo Nordisk A/S
Novo Nordisk A/S (NVO): 115 pipeline candidates · 46 upcoming catalysts · ~4 mo cash runway · 492 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.1 months
D/E 1.80 · 0% dilution
Lead: Phase 3
115 candidates
46 upcoming, next in ~26d
N/A
A transparent, data-derived signal for Novo Nordisk A/Sacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$194.3B
Cash
$26.5B
Quarterly Burn
$52.0B
Runway
4.1 mo
Revenue
$309.1B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (115 candidates)
| Drug | Phase |
|---|---|
| atorvastatin | Phase 1 |
| basal insulin analogues | Phase 4 |
| cagrilintide | Phase 3 |
| cagrilintide + semaglutide | Phase 2 |
| cagrilintide b | Phase 1 |
| cagrilintide d | Phase 1 |
| cagrisema | Phase 2 |
| cagrisema a | Phase 1 |
| cdr132l | Phase 2 |
| concizumab | Phase 3 |
Showing 10 of 115 candidates. Sign up for full pipeline.
Upcoming Catalysts (46)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,271
Total value held
$12.94B
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 31,024,311 | $1.14B |
| citadel advisors llc | 20,139,625 | $740.1M |
| dodge & cox | 19,333,750 | $710.5M |
| franklin resources inc | 16,083,479 | $591.1M |
| jane street group, llc | 12,881,307 | $473.4M |
| morgan stanley | 10,869,200 | $399.4M |
| bank of america corp /de/ | 10,769,699 | $395.8M |
| ubs group ag | 9,428,026 | $346.5M |
| d. e. shaw & co., inc. | 9,311,206 | $342.2M |
| folketrygdfondet | 9,080,820 | $333.7M |
Showing top 10 of 1,271 institutional holders of Novo Nordisk A/S. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Novo Nordisk A/S's pipeline?
Novo Nordisk A/S (NVO) has 115 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Novo Nordisk A/S's lead drug candidate?
Novo Nordisk A/S's most advanced tracked candidate is atorvastatin (Phase 1) for Obesity.
What is Novo Nordisk A/S's next catalyst?
Novo Nordisk A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. O" — expected July 14, 2026.
What is Novo Nordisk A/S's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Novo Nordisk A/S has approximately 4.1 months of cash runway.
What is Novo Nordisk A/S's market capitalization?
Novo Nordisk A/S's market capitalization is approximately $194.3B.
Get the full picture on Novo Nordisk A/S
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.